8-K - AWHL - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Dateof Report (Date of earliest event reported): January 6, 2025

AspiraWomen’s Health Inc.

(Exactname of Registrant as Specified in Its Charter)

Delaware	001-34810	33-0595156
(State or Other Jurisdiction of Incorporation)	(Commission<br><br> <br>File Number)	(IRS Employer Identification No.)

12117 Bee Caves Road<br><br> <br>Building III<br><br> <br>Suite 100
Austin, Texas	78738
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s

Telephone Number, Including Area Code: 512 519-0400

(FormerName or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications<br>pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material<br>pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br>communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br>communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common<br> Stock, par value $0.001 per share	AWH	The<br> Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of CertainOfficers; Compensatory Arrangements of Certain Officers.

On January 6, 2025, Aspira Women’s Health Inc. (the “Company”) accepted the resignation for personal reasons of John Kallassy, the Company’s Interim Chief Financial Officer, effective on January 10, 2025. The Company’s Chief Executive Officer, Dr. Sandra Milligan, will be the Company’s principal accounting officer for the present time.

In addition, the Board of Directors of the Company has approved the reinstatement of Dr. Milligan’s full salary retroactive to December 16, 2024.

| -2- |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aspira Women’s Health Inc.
Date: January 7, 2025	By:	/s/Sandra Milligan
		Sandra<br> Milligan, Interim Chief Executive Officer

| -3- |

| --- |